Abstract
BACKGROUND: Conduction system pacing, including His bundle pacing and left bundle branch area pacing, has emerged as a physiological alternative to biventricular pacing (BiVP) for cardiac resynchronisation therapy (CRT). BiVP benefits patients with left bundle branch block (LBBB), but outcomes in non-LBBB morphologies are inconsistent. We synthesised the evidence for CSP in heart failure patients with non-LBBB conduction patterns. METHODS: We performed a systematic review and meta-analysis (PROSPERO CRD420251015905) of 21 studies (11 with quantitative data; n = 480). Comparative outcomes (CSP vs. BiVP) and baseline vs. follow-up CSP changes were pooled. Primary endpoints were left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), New York Heart Association (NYHA) class, and QRS duration. Secondary endpoints included heart failure hospitalisation and all-cause mortality. RESULTS: In head-to-head analyses (198 patients; 99 per arm), CSP conferred a mean + 5.83% LVEF benefit (95% CI 3.06-8.60; p < 0.0001; I(2) = 0%), reduced LVEDD by 3.87 mm (95% CI 2.53-5.21; p < 0.001), improved NYHA class by -0.30 (95% CI -0.46 to -0.13; p = 0.0004), and narrowed QRS (SMD -0.91; 95% CI -1.18 to -0.64; p < 0.00001). CSP also halved HF hospitalisation risk (RR 0.44; 95% CI 0.24-0.81; p = 0.008; I(2) = 0%). In single-arm baseline and follow-up analyses (480 patients), CSP yielded a mean + 8.91% LVEF, -2.95 mm LVEDD, SMD -1.37 NYHA, and SMD -1.21 QRS (p < 0.0001). CONCLUSION: In non-LBBB heart failure, CSP delivers substantial improvements in ventricular systolic function, reverse remodelling, symptoms, and electrical synchrony versus BiVP, with reduced HF hospitalisation. These findings position CSP as a promising BiVP strategy for a traditionally non-responder subgroup and warrant confirmation in large, randomised trials.